BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 10932302)

  • 1. Cevimeline (Evoxac) for dry mouth.
    Med Lett Drugs Ther; 2000 Aug; 42(1084):70. PubMed ID: 10932302
    [No Abstract]   [Full Text] [Related]  

  • 2. A new medication for treatment of dry mouth in Sjögren's syndrome.
    al-Hashimi I; Taylor SE
    Tex Dent J; 2001 Apr; 118(3):262-6. PubMed ID: 11404944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Artificial saliva products and drugs to treat xerostomia.
    Wynn RL; Meiller TF
    Gen Dent; 2000; 48(6):630-6. PubMed ID: 12004654
    [No Abstract]   [Full Text] [Related]  

  • 4. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca.
    Petrone D; Condemi JJ; Fife R; Gluck O; Cohen S; Dalgin P
    Arthritis Rheum; 2002 Mar; 46(3):748-54. PubMed ID: 11920411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical significance of cevimeline hydrochloride in the treatment of dry mouth in patients with Sjögren's syndrome].
    Ogawa N; Shimoyama K; Karasawa H; Fukushima T; Masaki Y; Wano Y; Hirose Y; Sugai S
    Nihon Rinsho Meneki Gakkai Kaishi; 2004 Oct; 27(5):330-7. PubMed ID: 15559322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of muscarinic agonists in the treatment of Sjögren's syndrome.
    Fox RI; Konttinen Y; Fisher A
    Clin Immunol; 2001 Dec; 101(3):249-63. PubMed ID: 11726216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing the effectiveness and adverse effects of pilocarpine and cevimeline in patients with hyposalivation.
    Farag AM; Holliday C; Cimmino J; Roomian T; Papas A
    Oral Dis; 2019 Nov; 25(8):1937-1944. PubMed ID: 31520497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial.
    Fife RS; Chase WF; Dore RK; Wiesenhutter CW; Lockhart PB; Tindall E; Suen JY
    Arch Intern Med; 2002 Jun; 162(11):1293-300. PubMed ID: 12038948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study.
    Ono M; Takamura E; Shinozaki K; Tsumura T; Hamano T; Yagi Y; Tsubota K
    Am J Ophthalmol; 2004 Jul; 138(1):6-17. PubMed ID: 15234277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open-label, long-term safety study of cevimeline in the treatment of postirradiation xerostomia.
    Chambers MS; Jones CU; Biel MA; Weber RS; Hodge KM; Chen Y; Holland JM; Ship JA; Vitti R; Armstrong I; Garden AS; Haddad R
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1369-76. PubMed ID: 17855005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sjögren's syndrome patients presenting with hypergammaglobulinemia are relatively unresponsive to cevimeline treatment.
    Komai K; Shiozawa K; Tanaka Y; Yoshihara R; Tanaka C; Sakai H; Yamane T; Murata M; Tsumiyama K; Hashiramoto A; Shiozawa S
    Mod Rheumatol; 2009; 19(4):416-9. PubMed ID: 19452244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the use of sialogogues in the clinical management of patients with xerostomia.
    Chainani-Wu N; Gorsky M; Mayer P; Bostrom A; Epstein JB; Silverman S
    Spec Care Dentist; 2006; 26(4):164-70. PubMed ID: 16927740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing salivary gland hypofunction--Part two.
    Muzyka BC
    Pract Proced Aesthet Dent; 2002 Apr; 14(3):262. PubMed ID: 12004635
    [No Abstract]   [Full Text] [Related]  

  • 14. The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren's syndrome in southern Chinese patients: a randomised double-blind, placebo-controlled crossover study.
    Leung KC; McMillan AS; Wong MC; Leung WK; Mok MY; Lau CS
    Clin Rheumatol; 2008 Apr; 27(4):429-36. PubMed ID: 17899308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of cevimeline to improve oral health in patients with postradiation xerostomia.
    Witsell DL; Stinnett S; Chambers MS
    Head Neck; 2012 Aug; 34(8):1136-42. PubMed ID: 22231734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New approaches to preventing xerostomia.
    J Support Oncol; 2006 Feb; 4(2):87-8. PubMed ID: 16499130
    [No Abstract]   [Full Text] [Related]  

  • 17. Salivary hypofunction: An update on therapeutic strategies.
    Salum FG; Medella-Junior FAC; Figueiredo MAZ; Cherubini K
    Gerodontology; 2018 Dec; 35(4):305-316. PubMed ID: 29956369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the discontinuation rates and side-effect profiles of pilocarpine and cevimeline for xerostomia in primary Sjögren's syndrome.
    Noaiseh G; Baker JF; Vivino FB
    Clin Exp Rheumatol; 2014; 32(4):575-7. PubMed ID: 25065774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salivary dysfunction associated with systemic diseases: systematic review and clinical management recommendations.
    von Bültzingslöwen I; Sollecito TP; Fox PC; Daniels T; Jonsson R; Lockhart PB; Wray D; Brennan MT; Carrozzo M; Gandera B; Fujibayashi T; Navazesh M; Rhodus NL; Schiødt M
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Mar; 103 Suppl():S57.e1-15. PubMed ID: 17379156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cevimeline.
    Weber J; Keating GM
    Drugs; 2008; 68(12):1691-8. PubMed ID: 18681491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.